Jesse Boumelha

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.

Dendritic cells control tertiary lymphoid structure development and maintenance in cancer.

Journal: Science (New York, N.Y.)
Published: July 16, 2026

Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Journal: Nature
Published: January 14, 2026

Targeting neoantigens conserved across organs and species overcomes tumor immune escape.

Targeting neoantigens conserved across organs and species overcomes tumor immune escape.

Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025

Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer.

Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer.

Journal: bioRxiv : the preprint server for biology
Published: January 07, 2025

Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis.

Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis.

Journal: Science (New York, N.Y.)
Published: September 05, 2024

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Journal: Nature communications
Published: January 23, 2024

Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer.

Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer.

Journal: Nature immunology
Published: December 02, 2023

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.

Journal: Cancer research
Published: August 30, 2023

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

Journal: Nature genetics
Published: June 25, 2023

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.

Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 02, 2023

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Journal: Science advances
Published: July 20, 2022

Lung adenocarcinoma promotion by air pollutants.

Lung adenocarcinoma promotion by air pollutants.

Journal: Nature
Published: June 17, 2022
Showing 1-12 of 14

Last Updated: 09/26/2026